The days may be getting shorter, but the US FDA shows no signs of slowing down, handing out three new product approvals and one complete response letter on Nov. 2.
Undoubtedly the most controversial of the approvals was that for AcelRx Pharmaceuticals Inc.'s Dsuvia, a sufentanil sublingual tablet
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?